Catalyst Pharmaceuticals, Inc. (CPRX) Stock Overview
Explore Catalyst Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Catalyst Pharmaceuticals, Inc. (CPRX)
Key Financials
Key Financials
Market Cap
3.9B
P/E Ratio
17.49
EPS (TTM)
$2.56
ROE
0.24%
CPRX Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Catalyst Pharmaceuticals, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of CPRX on the NASDAQ shows an RSI of 72.01, suggesting the stock is in a an overbought condition. Our forecasting models predict a 12-month price target of $29.96 for the NASDAQ listing.
Key metrics behind Catalyst Pharmaceuticals, Inc.'s NASDAQ-traded stock include a P/E ratio of 17.49 and a market capitalization of 3.9B. Combined with our AI analysis, these give both institutional and retail investors a clear view of CPRX on the NASDAQ.